EP0581793A1 - Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents - Google Patents

Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents

Info

Publication number
EP0581793A1
EP0581793A1 EP19920908170 EP92908170A EP0581793A1 EP 0581793 A1 EP0581793 A1 EP 0581793A1 EP 19920908170 EP19920908170 EP 19920908170 EP 92908170 A EP92908170 A EP 92908170A EP 0581793 A1 EP0581793 A1 EP 0581793A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
group
administered
phosphonate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920908170
Other languages
German (de)
French (fr)
Inventor
Hassan Salari
Robert Bittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of EP0581793A1 publication Critical patent/EP0581793A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4081—Esters with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/303—Cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Definitions

  • This invention pertains to the synthesis and use as therapeutic agents of a group of substances with a glycerol backbone or aliphatic chain structure linked to phosphonocholine, phosphinocholine, phosphonoinositol, phosphinoinositol, or other phosphorus-containing head groups.
  • the substance has anti-cancer, anti-inflammatory, anti-allergy, or anti-cardiovascular disease properties.
  • West German Patent No. P 0230575A2 dated April 12, 1986, discloses a group of glycerophosphohpids compounds having an alkyl chain of C2-C22 and a methoxy group at the sn-2 position and a phosphocholine at the sn-3 position. These compounds are stated to be useful as anticancer agents.
  • None of these patents discloses a substance with a glycerol backbone linked to a phosphorus atom with a polar head group used as an anti-cancer, anti-inflammatory, anti-allergy, or anti-cardiovascular disease treating agents.
  • the present invention provides anti-leukemic phospholipids of the general formula:
  • T is an oxygen atom
  • U is an oxygen atom
  • NH is an aliphatic chain such as hexadecyl or octadecyl
  • R 2 is a methyl group when U is oxygen or when U is NH
  • X is a methylene group
  • n is 0 to 14
  • R 3 is either an oxygen atom or a methylene group
  • m is 2, 3, 4, 5,
  • R 4 , R 5 and R 6 represent alkyl groups containing 1 to 3 carbon atoms.
  • Phosphonolipids of the general formula R-P(O)(O-)OR' wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
  • n 0 or 1
  • R 1 and R 2 are as defined in claim 1
  • R 4 is an alkyl group such as methyl, ethyl, n-propyl, or isopropyl.
  • the phosphonate or phosphinate compounds as claimed in described include either of the opposite stereochemical configurations [( R) or ( S)], or a mixture thereof.
  • a phosphinate for treatment of leukemic cells having the formula:
  • R 1 is a long-chain alkyl group
  • R 2 is a methyl group
  • n 0 or
  • R 3 is N + (CH 3 ) 3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
  • the compound as identified in the second paragraph of this summary can be used as an agent in inhibiting cancer cell growth when the compound is administered at a concentration in the range of 5 mg/l to 50 mg/l, and pharmaceutically acceptable acid or salts thereof; and a pharmaceutically acceptable carrier.
  • the compound as identified in the third paragraph of this summary can be used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier.
  • the compounds identithis summary can be used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier.
  • the phosphonates or phosphinates as identified in the second, third, fourth, fifth, and sixth paragraphs of this summary can be used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
  • a method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a compound of the formula:
  • a method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphonolipid of the general formula: R-P(O)(O-)(OR), wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
  • a method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate of the general formula:
  • n 0 or 1
  • R 1 and R 2 are as defined in claim 1
  • R 4 is an alkyl group such as methyl, ethyl, n- propyl, or isopropyl.
  • the phosphonate or phosphinate compound can includes either of the opposite stereochemical configurations [(R ) or (S)], or a mixture thereof.
  • a method of treating leukemic cells in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate having the formula:
  • R 1 is a long-chain alkyl group
  • R 2 is a methyl group
  • n 0 or
  • R 3 is N + (CH 3 ) 3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
  • the present invention also provides phospholipids with the following structures:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and n are as defined above.
  • the present invention provides phospholipids with an inositol group for use as anti-inflammatory agents:
  • R 1 is as defined herein above.
  • phosphonates and phosphinates are useful as anti-cancer agents since they inhibit growth of leukemic and tumor cells, as anti-inflammatory and anti-allergic agents, and as anti-cardiovascular agents.
  • the invention also involves the use of one or several of the above-mentioned phosphonates and phosphinates for treatment of cardiovascular diseases, such as septic shock (cardiogenic shock, thrombosis and others) when given at 5-50 mg/l in a pharmaceutically acceptable acid or salt thereof, and carrier.
  • septic shock cardiac shock, thrombosis and others
  • the invention is also directed to the use of phosphonates and phosphinates in the treatment of malignant cells, solid tumors of any type, leukemia and in bone marrow transplantation.
  • the invention also pertains to the use of phosphonates in the treatment of inflammatory diseases of any form, for example, arthritis, inflammatory bowel diseases, colitis, and pulmonary inflammation.
  • the invention relates to the use of phosphonates in the treatment of allergic diseases of any form, such as asthma, allergic rhenitis, hay fever, skin rashes and seasonal allergies.
  • the phosphonocholines and phosphonoglycerols can be synthesized according to the following reaction sequence:
  • Diethyl phosphite is treated with hexadecyl (or octadecyl) bromide in a Michaelis-Becker reaction, giving the corresponding diethyl ester.
  • the alkyl phosphonic acid is formed in situ from the ester , then treated with 2.1 equivalents of pyridine at 0°C in tetrahydrofuran, followed by 2.1 equivalents of oxaloyl chloride at -78°C under nitrogen.
  • the phosphonic acid dichloride thus obtained is treated with either (R )-2-O -benzylglycerol (for conversion to phosphonoglycerol) or with ethylene glycerol to give the phospholane intermediate, which is reacted with triethylamine in acetonitrile at 75°C in a pressure bottle to give phosphonocholine.
  • the intermediates and products are purified by chromatography on silica gel G or by high-pressure liquid chromatography.
  • the structures are established by nuclear magnetic resonance spectroscopy, mass spectrometry, and by elemental analysis.
  • the phosphonoinositol is prepared by the following reaction sequence:
  • the phosphonoinositol is produced by reacting hexadecyl (or octadecyl) bromide with tris(trimethylsilyl)phosphite under argon at 135°C to form the alkyl phosphonic acid. After the excess phosphite is removed by distillation, the residue is purified and coupled to pentabenzylinositol in the presence of trichloroacetonitrile in pyridine at 60°C to form pentabenzylinositol phosphonate.
  • the phosphonoethanolamine is prepared by the following reaction sequence:
  • the phosphonoserine is prepared by the following reaction
  • N-tritylserine methyl ester is added to a solution of the alkyl phosphonic acid dichloride in tetrahydrofuran and diisopropylethylamine in tetrahydrofuran.
  • the intermediate N-tritylserine methyl ester is purified by silica gel chromatography, then subjected to detritylation with 0.1 M hydrochloric acid and alkaline hydrolysis of the methyl ester.
  • the product is purified by Dowex 50W-X8 (H + form) followed by silica gel chromatography.
  • Phosphonocholines are prepared by the following reaction sequence:
  • the r ⁇ c-phosphonic acid shown above is prepared by proceeding according to the following sequence of reactions.
  • a n-alkyl allyl ether is reacted with methanol in the presence of zinc oxide and iodine; alkyl groups other than methyl can be conveniently introduced by this method (reference: Rosenthal, A.F.; Kosolapoff, G.M.; Geyer, R.P. Recl. Trav. Chim. Pays-Bas 1964, 83, 1273).
  • the 1 - O-alkyl-2-O -methyliodopropane is treated with triethyl phosphite, affording the corresponding diethyl phosphonate ester, which is hydrolyzed to give the phosphonic acid.
  • Phosphonocholine is obtained by reaction with dry choline tosylate (9 equivalents) in the presence of trichloroacetonitrile in pyridine at 50°C for 2 days.
  • the corresponding glycerol-linked phosphonoethanolamine is prepared by reaction of the phosphonic acid with N-(tert-butoxycarbonyl)- ethanolamine (N-t-Boc-ethanolamine) in the presence of trichloroacetonitrile or 1H -tetrazole; after purification of the coupling product by silica gel chromatography, the Boc protecting group is removed under standard conditions (50% trifluoroacetic acid in dichloromethane at 0°C).
  • the corresponding glycerol-linked phosphonoserine is prepared in a similar fashion, using N-tritylserine methyl ester for coupling with the phosphonic acid.
  • the acid-labile trityl group is removed by treatment with 0.1 M hydrochloric acid in tetrahydrofuran-water (1:1), and then the methyl ester is hydrolyzed by using 0.2 M sodium hydroxide. Purification is by silica gel chromatography.
  • Isosteric phosphonates are prepared according to the following reaction sequences:
  • Isosteric phosphonocholine and isosteric phosphonoinositol are prepared from 1 ,2,5,6-diisopropylidene-D-mannitol as outlined above.
  • O-benzylation is carried out at the 3 and 4 positions, then the isopropylidene groups are removed and the primary alcohols are alkylated with long-chain alkyl groups via the mesylates or similar alkylati ⁇ g agents. Methylation is carried out at the 2 and 5 positions.
  • Phosphonoglycerols are available by a similar route.
  • octadecyl glycidol gives the enantiomeric phosphonolipid.
  • the nonisosteric phosphinocholines are prepared according to the following reaction sequence:
  • 1-O-alkyl-2-O-methyliodopropane gives isopropyl 2-methoxy-3- O-alkylpropyl(allyl)phosphinate, which is cleaved with osmate-periodate, and reduced with sodium borohydride in ethanol to the hydroxyethylphosphinate. The latter is converted to the mesylate and allowed to react with aqueous dimethylamine, followed by quaternization to give the phosphinate compound.
  • Isosteric phosphinocholines and phosphinoinositols are prepared according to the following reaction sequences:
  • Isosteric phosphinocholine is prepared as outlined by the reaction sequence shown above. Wittig reaction of the aldehyde followed by hydroboration gives the alcohol, which is then converted into the desired phosphinate. Hydroboration gives an alcohol (not shown) that can be coupled to a protected inositol to yield the corresponding phosphinoinositol. Mesylation of the alcohol gives the phosphinate compound, which is aminated, then treated with methyl iodide, and the phosphonate ester is hydrolyzed to give the isosteric phosphinocholine.
  • the distance between the phosphorus and nitrogen atoms in the phosphonolipids is varied by using procedures known in the corresponding phosphate-containing compounds (references: All, S.;
  • Table I shows the effect of various concentrations of the phosphonate of the following formula on the growth of WEHI-3B cells:
  • Table II shows results of thymidine uptake by WEHI-3B and HL-60 cells during 48 hours of incubation.
  • Thymidine uptake during 48 hours phosphonate thymidine uptake (% of control) concentration ( ⁇ M) WEHI-3B cells HL-60 cells
  • Table III shows the results of thymidine uptake by WEHI-3B and
  • Thymidine uptake during 72 hours phosphonate thymidine uptake (% of control)
  • Table V demonstrates the effect of phosphonate of the above structure on the incorporation of thymidine into DNA of the C-41 cell line (a human cervical tumor cell) Table V
  • Table VI shows the effect of the above phosphonate on tumor growth in mice.
  • BALB/C mice were injected with 3-Lewis lung carcinoma under the skin at the back. Three days after injection of tumor cells the treatment was initiated with 50 mg/day orally once a day. In the control group the mice received only the carrier mucilage of tragacanth. As seen in Table VI, in control animals the first sign of a detectable tumor was observed after the seventh day of post cell injection. In the phosphonate-treated animals, the tumor growth was retarded by approximately 6 days. The tumor size in the
  • Example 1 Effect of the phosphonate of the following formula on the activation of human neutrophils
  • Example 2 Effect of phosphonate on neutrophil degranulation and lysosomal enzyme release (elastase)
  • Petri dishes were coated with [ 3 H]elastin and were used to assess the release of elastase.
  • Neutrophils (10 6 ) in 500 ⁇ l of medium were added to each Petri dish well. Addition of 1 ⁇ M FMLP for 1 hour at 37°C
  • CPPD calcium pyrophosphate dihydrate
  • MSU monosodium urate
  • Asthma is an allergic disease caused by the contraction of airway
  • Thrombosis is the result of activation of platelets by agents such as
  • PAF platelet activating factor
  • Phosphonates also inhibited serotonin release from platelets activated with thrombin or PAF. As seen in Table XIII, phosphonate at 10 ⁇ M blocked serotonin release entirely.
  • Phosphonates were shown' to block PAF-induced hypotension in rats. When given at 5 mg/kg, phosphonates inhibited the hypotensive activity of PAF dramatically. As seen in Table XTV, normal rat blood pressure was about 150 mm Hg, and this dropped to about 40 mm Hg after administration of PAF (10 ⁇ g/kg). Animals given phosphonates (5 mg/kg) had only slightly reduced blood pressure after the injection of PAF, suggesting that phosphonates are anti-hypotensive agents.
  • An effective concentration of phosphonate (normally 5-50 mg/l) can be given orally, intravenously (i.v.), intramuscularly (i.m.) or subcutaneously (s.c.), in the form of tablets (orally), capsules (orally), or injection ampules (i.v., i.m., s.c).
  • the drug can be applied in the form of a rubbing cream.
  • Tablets can be prepared via compression of 50 mg of phosphonates, 200 mg of lactose, and 50 mg Avicel (TM) .
  • Capsules are made by making bilayers of liposomal phosphonates in the concentrations of 5-50 mg with lecithin.
  • Injection solutions are made either in water or propylene glycol with an upwardly adjusted pH in phosphate buffer.
  • the drag solution is sterilized through a filter of 0.22 mm.
  • Solutions can be made in 20% propylene glycol with about 0.5% of a preservative such as ascorbic acid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à la synthèse et à l'utilisation, comme agents thérapeutiques, d'un groupe de substances présentant un squelette de glycérol ou une structure de chaîne aliphatique lié(e) à un atome de phosphore ou à un groupe de tête polaire. Selon le groupe de tête polaire, la substance présente des caractéristiques anticancéreuses, anti-inflammatoires, anti-allergiques ou agissant contre les maladies cardiovasculaires. On décrit aussi des composés de la formule (I) et (II), où n vaut de 0 à 14 et R1 représente un groupe alkyle C12-C20, R2 représente un groupe méthyle et R3 représente un groupe de tête d'analogue d'inositol, un groupe (CH2)mN+(CH3)3 où m vaut de 2 à 10, un groupe de tête de sérine ou un groupe de tête d'éthanolamine, ou de la formule (III) où R1 et R2 sont tels que décrits ci-dessus, n = 0 ou 1, et R3 représente (CH2)mN+(CH3)3 (m=2-10). L'invention se rapporte en outre à la synthèse et à l'utilisation, comme agents thérapeutiques, de substances ne possédant pas de squelette de glycérol, mais qui présentent une structure de chaîne aliphatique directement liée à un atome de phosphore de la formule générale R-P(0)(0-) OR', où R représente un groupe alkyle à chaîne longue tel que hexadécyle ou octadécyle et R' représente un groupe de tête tel que choline, glycérol, inositol, éthanolamine ou sérine.The invention relates to the synthesis and use, as therapeutic agents, of a group of substances having a glycerol skeleton or an aliphatic chain structure linked to a phosphorus atom or to a head group polar. According to the polar head group, the substance has anti-cancer, anti-inflammatory, anti-allergic or anti-cardiovascular characteristics. Compounds of the formula (I) and (II) are also described, where n is from 0 to 14 and R1 represents a C12-C20 alkyl group, R2 represents a methyl group and R3 represents a head group of analog of inositol, a group (CH2) mN + (CH3) 3 where m is from 2 to 10, a serine head group or an ethanolamine head group, or of formula (III) where R1 and R2 are as described above, n = 0 or 1, and R3 represents (CH2) mN + (CH3) 3 (m = 2-10). The invention further relates to the synthesis and use, as therapeutic agents, of substances which do not have a glycerol skeleton, but which have an aliphatic chain structure directly linked to a phosphorus atom of the general formula RP (0) (0-) OR ', where R represents a long chain alkyl group such as hexadecyl or octadecyl and R' represents a leading group such as choline, glycerol, inositol, ethanolamine or serine.

Description

PHOSPHONATES AND PHOSPHINATES AS ANTI-CANCER, -INFLAMMATORY, -ALLERGY AND -MYOCARDITIS AGENTS
FIELD OF THE INVENTION
This invention pertains to the synthesis and use as therapeutic agents of a group of substances with a glycerol backbone or aliphatic chain structure linked to phosphonocholine, phosphinocholine, phosphonoinositol, phosphinoinositol, or other phosphorus-containing head groups. Depending on the polar head group, the substance has anti-cancer, anti-inflammatory, anti-allergy, or anti-cardiovascular disease properties.
B ACKGOUND OF THE INVENTION
West German Patent No. P 0230575A2, dated April 12, 1986, discloses a group of glycerophosphohpids compounds having an alkyl chain of C2-C22 and a methoxy group at the sn-2 position and a phosphocholine at the sn-3 position. These compounds are stated to be useful as anticancer agents.
U.S. Patent No. 4,408,052, dated February 25, 1981, assigned to Takeda Chemical Industries, Osaka, Japan, claims a group of phospholipid carbamates as useful as antitumor agents.
Canadian Patent No. 1,248,534, dated January 10, 1989, granted to Takeda Chemical Industries of Japan, protects a group of ketolyso phospholipids, which purportedly are useful as antitumor agents. U.S. Patent No.4,515,722, dated May 7, 1985, granted to Merck Sharp & Dohme, protects a group of phosphatidylinositol analogs which are evidently effective in inhibiting phospholipase C and thereby have utility as anti-inflammatory and analgestic agents.
None of these patents discloses a substance with a glycerol backbone linked to a phosphorus atom with a polar head group used as an anti-cancer, anti-inflammatory, anti-allergy, or anti-cardiovascular disease treating agents.
SUMMARY OF THE INVENTION
The present invention provides anti-leukemic phospholipids of the general formula:
wherein T is an oxygen atom, U is an oxygen atom, or NH, R1 is an aliphatic chain such as hexadecyl or octadecyl, R2 is a methyl group when U is oxygen or when U is NH, X is a methylene group, n is 0 to 14, R3 is either an oxygen atom or a methylene group, m is 2, 3, 4, 5,
6, 7, 8, or 9, and R4, R5 and R6 represent alkyl groups containing 1 to 3 carbon atoms.
A compound of the formula:
wherein n is 0 to 14 and R1 is an alkyl group of C1 2-C20 ; wherein R 2 is a methyl group; and wherein R3 is an inositol analog head group, a (CH2)mN + (CH3)3 group with m = 2 to 10, a serine head group, or an ethanolamine head group. A phosphonate compound of the formula:
wherein R is an alkyl group such as hexadecyl or octadecyl, m = 0 or 1, n = 2 - 10, or the enantiomer thereof, or a mixture of stereoisomers.
Phosphonolipids of the general formula R-P(O)(O-)OR' wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
Phosphinates of the general formula:
wherein n = 0 or 1, R1 and R2 are as defined in claim 1, and R3 is an inositol or N+(R4)3 group and m = 2 - 10, and R4 is an alkyl group such as methyl, ethyl, n-propyl, or isopropyl.
The phosphonate or phosphinate compounds as claimed in described include either of the opposite stereochemical configurations [( R) or ( S)], or a mixture thereof.
A phosphinate for treatment of leukemic cells having the formula:
wherein R1 is a long-chain alkyl group, R2 is a methyl group, n = 0 or
1, m = 2 or 3, and R3 is N+(CH3)3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
The compound as identified in the second paragraph of this summary can be used as an agent in inhibiting cancer cell growth when the compound is administered at a concentration in the range of 5 mg/l to 50 mg/l, and pharmaceutically acceptable acid or salts thereof; and a pharmaceutically acceptable carrier. The compound used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier.
The compound as identified in the third paragraph of this summary can be used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier.
The compounds identithis summary can be used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier. The phosphonates or phosphinates as identified in the second, third, fourth, fifth, and sixth paragraphs of this summary can be used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
A method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a compound of the formula:
wherein n is 0 to 14 and R1 is an alkyl group of C12-C20 ; wherein R2 is a methyl group; and wherein R3 is an inositol analog head group, a (CH2)mN+(CH3)3 group with m = 2 to 10, a serine head group, or an ethanolamine head group.
A method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a compound of the formula: wherein R is an alkyl group such as hexadecyl or octadecyl, m = 0 or 1, n = 2 - 10, or the enantiomer thereof, or a mixture of stereoisomers.
A method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphonolipid of the general formula: R-P(O)(O-)(OR), wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
A method of treating cancer, inflammation, allergy or cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate of the general formula:
wherein n = 0 or 1, R1 and R2 are as defined in claim 1, and R3 is an inositol or N+(R4)3 group and m = 2 - 10, and R4 is an alkyl group such as methyl, ethyl, n- propyl, or isopropyl.
The phosphonate or phosphinate compound can includes either of the opposite stereochemical configurations [(R ) or (S)], or a mixture thereof.
A method of treating leukemic cells in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate having the formula:
wherein R1 is a long-chain alkyl group, R2 is a methyl group, n = 0 or
1, m = 2 or 3, and R3 is N+(CH3)3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
The present invention also provides phospholipids with the following structures:
and
wherein R1, R2, R3, R4, R5, R6 and n are as defined above.
The present invention provides phospholipids with an inositol group for use as anti-inflammatory agents:
wherein R1 is as defined herein above.
These phosphonates and phosphinates are useful as anti-cancer agents since they inhibit growth of leukemic and tumor cells, as anti-inflammatory and anti-allergic agents, and as anti-cardiovascular agents.
The invention also involves the use of one or several of the above-mentioned phosphonates and phosphinates for treatment of cardiovascular diseases, such as septic shock (cardiogenic shock, thrombosis and others) when given at 5-50 mg/l in a pharmaceutically acceptable acid or salt thereof, and carrier.
The invention is also directed to the use of phosphonates and phosphinates in the treatment of malignant cells, solid tumors of any type, leukemia and in bone marrow transplantation.
The invention also pertains to the use of phosphonates in the treatment of inflammatory diseases of any form, for example, arthritis, inflammatory bowel diseases, colitis, and pulmonary inflammation.
Further, the invention relates to the use of phosphonates in the treatment of allergic diseases of any form, such as asthma, allergic rhenitis, hay fever, skin rashes and seasonal allergies. DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
Production of the Phospholipids of the Invention
(a) Synthesis of Phosphonocholines and Phosphonoglycerols
The phosphonocholines and phosphonoglycerols can be synthesized according to the following reaction sequence:
Diethyl phosphite is treated with hexadecyl (or octadecyl) bromide in a Michaelis-Becker reaction, giving the corresponding diethyl ester. The alkyl phosphonic acid is formed in situ from the ester , then treated with 2.1 equivalents of pyridine at 0°C in tetrahydrofuran, followed by 2.1 equivalents of oxaloyl chloride at -78°C under nitrogen. The phosphonic acid dichloride thus obtained is treated with either (R )-2-O -benzylglycerol (for conversion to phosphonoglycerol) or with ethylene glycerol to give the phospholane intermediate, which is reacted with triethylamine in acetonitrile at 75°C in a pressure bottle to give phosphonocholine. The intermediates and products are purified by chromatography on silica gel G or by high-pressure liquid chromatography. The structures are established by nuclear magnetic resonance spectroscopy, mass spectrometry, and by elemental analysis.
(b) Synthesis of phosphonoinositol
The phosphonoinositol is prepared by the following reaction sequence:
The phosphonoinositol is produced by reacting hexadecyl (or octadecyl) bromide with tris(trimethylsilyl)phosphite under argon at 135°C to form the alkyl phosphonic acid. After the excess phosphite is removed by distillation, the residue is purified and coupled to pentabenzylinositol in the presence of trichloroacetonitrile in pyridine at 60°C to form pentabenzylinositol phosphonate. The coupling product is purified by chromatography on silica gel, the benzyl groups are removed by catalytic hydrogenolysis, and the product phosphonoinositol is purified by cation exchange and silica gel chromatography. (c) Synthesis of phosphonoethanolamine
The phosphonoethanolamine is prepared by the following reaction sequence:
To a solution of the alkyl phosphonic acid dichloride and triethylamine in tetrahydrofuran is added a solution of 2-aminoethanol in tetrahydrofuran. Evaporation of the solvent under reduced pressure gives the intermediate phospholane, which is purified by column chromatography, dissolved in 2-propanol, and then hydrolyzed by using a mixture of glacial acetic acid in water (1:4 by volume).
(d) Synthesis of phosphonoserine
The phosphonoserine is prepared by the following reaction
To a solution of the alkyl phosphonic acid dichloride in tetrahydrofuran and diisopropylethylamine in tetrahydrofuran is added a solution of N-tritylserine methyl ester in tetrahydrofuran. The intermediate N-tritylserine methyl ester is purified by silica gel chromatography, then subjected to detritylation with 0.1 M hydrochloric acid and alkaline hydrolysis of the methyl ester. The product is purified by Dowex 50W-X8 (H+ form) followed by silica gel chromatography.
(e) Production of glycerol-linked phosphonolipids
Phosphonocholines are prepared by the following reaction sequence:
The rαc-phosphonic acid shown above is prepared by proceeding according to the following sequence of reactions. First, a n-alkyl allyl ether is reacted with methanol in the presence of zinc oxide and iodine; alkyl groups other than methyl can be conveniently introduced by this method (reference: Rosenthal, A.F.; Kosolapoff, G.M.; Geyer, R.P. Recl. Trav. Chim. Pays-Bas 1964, 83, 1273). The 1 - O-alkyl-2-O -methyliodopropane is treated with triethyl phosphite, affording the corresponding diethyl phosphonate ester, which is hydrolyzed to give the phosphonic acid. Phosphonocholine is obtained by reaction with dry choline tosylate (9 equivalents) in the presence of trichloroacetonitrile in pyridine at 50°C for 2 days.
The corresponding glycerol-linked phosphonoethanolamine is prepared by reaction of the phosphonic acid with N-(tert-butoxycarbonyl)- ethanolamine (N-t-Boc-ethanolamine) in the presence of trichloroacetonitrile or 1H -tetrazole; after purification of the coupling product by silica gel chromatography, the Boc protecting group is removed under standard conditions (50% trifluoroacetic acid in dichloromethane at 0°C).
The corresponding glycerol-linked phosphonoserine is prepared in a similar fashion, using N-tritylserine methyl ester for coupling with the phosphonic acid. The acid-labile trityl group is removed by treatment with 0.1 M hydrochloric acid in tetrahydrofuran-water (1:1), and then the methyl ester is hydrolyzed by using 0.2 M sodium hydroxide. Purification is by silica gel chromatography.
(f) Production of glycerol-linked isosteric phosphonates
Isosteric phosphonates are prepared according to the following reaction sequences:
Isosteric phosphonocholine and isosteric phosphonoinositol are prepared from 1 ,2,5,6-diisopropylidene-D-mannitol as outlined above. First, the O-benzylation is carried out at the 3 and 4 positions, then the isopropylidene groups are removed and the primary alcohols are alkylated with long-chain alkyl groups via the mesylates or similar alkylatiπg agents. Methylation is carried out at the 2 and 5 positions.
After catalytic hydrogenolysis, periodic acid cleavage gives the aldehyde. Reaction of the aldehyde with tetraisopropyl methylenebisphosphonate and n-butyllithium in hexane at 0°C gives the phosphonic ester, which is hydrolyzed to the corresponding phosphonic acid by using trimethylsilyl bromide followed by aqueous workup. The vinyl group is reduced, and the phosphonic acid is coupled to choline tosylate to give the desired
phosphonocholine compound or to suitably protected inositol, followed by deprotection, to give the desired phosphonoinositol compound. The products are purified by ion-exchange
chromatography followed by silica gel chromatography.
Phosphonoglycerols are available by a similar route.
An alternative procedure for making phosphonoinositols and phosphonocholines is illustrated below.
The above reaction sequence shows the use of (R)- O-hexadecyl or -octadecyl glycidol as the starting material. Use of (S)-hexadecyl or
octadecyl glycidol gives the enantiomeric phosphonolipid.
(g) Production of glycerol-linked phosphinocholines .
The nonisosteric phosphinocholines are prepared according to the following reaction sequence:
Reaction of diisopropylallylphosphinate with
1-O-alkyl-2-O-methyliodopropane gives isopropyl 2-methoxy-3- O-alkylpropyl(allyl)phosphinate, which is cleaved with osmate-periodate, and reduced with sodium borohydride in ethanol to the hydroxyethylphosphinate. The latter is converted to the mesylate and allowed to react with aqueous dimethylamine, followed by quaternization to give the phosphinate compound.
(h) Production of glycerol-linked isosteric phosphinates
Isosteric phosphinocholines and phosphinoinositols are prepared according to the following reaction sequences:
Isosteric phosphinocholine is prepared as outlined by the reaction sequence shown above. Wittig reaction of the aldehyde followed by hydroboration gives the alcohol, which is then converted into the desired phosphinate. Hydroboration gives an alcohol (not shown) that can be coupled to a protected inositol to yield the corresponding phosphinoinositol. Mesylation of the alcohol gives the phosphinate compound, which is aminated, then treated with methyl iodide, and the phosphonate ester is hydrolyzed to give the isosteric phosphinocholine.
(i) Production of agents with modified distances between the
phosphorus and nitrogen atoms
The distance between the phosphorus and nitrogen atoms in the phosphonolipids is varied by using procedures known in the corresponding phosphate-containing compounds (references: All, S.;
Bittman, R. Chem. Phys. Lipids 1989, 50, 11-21 ; Isaacson, Y.A.; Deroo,
P.W.; Rosenthal, A.F.; Bittman, R.; McIntyre, J.O.; Bock, H-G.; Gazzotti,
P.; Fleischer, S. J. Biol. Chem. 1979, 254, 117-126; Ukawa, K.;
Imamiya, E.; Yamamoto, H., et al. Chem. Pharm. Bull. 1989, 37,
1249-1255). One method for conversion of the glycerol derivative to the phosphonocholine analog with a variable number of methylene groups between the phosphorus and nitrogen atoms is shown below.
Biological Activity
1. Anti-cancer activity
Several laboratory tests have been conducted to establish that phosphonates kill cancer cells.
It has been discovered that a phosphonate of the following structure:
inhibits thymidine incorporation into DNA of several cancer cell lines. This behavior is indicative of anti-cancer activity.
Example 1
Experiments were performed with three different cell lines: (1) with a mouse myelomonocytic leukemic cell line (WEHI-3B cells), (2) a human myeloleukemic cell line (HL-60 and a human cervical tumor cell line (C-41)). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, mercaptoethanol (5 μg/ml), penicillin (50 units/ml), streptomycin (50 μg/ml), in an atmosphere of 5% CO2. The cells were passaged weekly by serial
1/10 to 1/10000 dilutions. The cell viability and growth were constantly monitored by staining with trypan blue exclusion dye or the incorporation of tritiated thymidine. 3H-Thymidine incorporation
Cells were placed in 96-well plates at 2 × 104 cells/ well in 200 μl of medium and another 5 μl of medium containing the drugs was added. Control cultures were incubated without drugs. Cells in 96-well plates were incubated in a CO2 incubator for 24 hours. The cells were then pulsed with 0.1 μCi of [3H]thymidine for 24 hours prior to the harvesting. The cells were harvested using a Brandel cell harvester model M-12, and collected on Whatman glass microfilters. The radioactivity associated with the filters was counted in a liquid scintillation counter and plotted as percent survival versus concentration of phosphonate, and the data were compared with
[3H]thymidine incorporation into the untreated cells.
Table I shows the effect of various concentrations of the phosphonate of the following formula on the growth of WEHI-3B cells:
Table I
Thymidine uptake during 24 hours phosphonate thymidine uptake(% of control) concentration (μM) mean ± s.d.
0 100
0.62 137 ±6
1.25 93 ± 7
2.5 91±4
5 88 ±11
10 76±6
20 48 ±4 0 43 ± 15
Table II shows results of thymidine uptake by WEHI-3B and HL-60 cells during 48 hours of incubation.
Table II
Thymidine uptake during 48 hours phosphonate thymidine uptake (% of control) concentration (μM) WEHI-3B cells HL-60 cells
Mean ± s.d. n=8
0 100 100
0.62 93 ± 6 84 ± 5
1.25 90 ± 5 76 ± 4
2.5 86 ± 8 63 ± 4
5 61 ± 6 24 ± 3
10 23 ± 2 3 ± 2
20 18 ± 8 1 ± 0
Table III shows the results of thymidine uptake by WEHI-3B and
HL-60 cells during 72 hours of incubation.
Table III
Thymidine uptake during 72 hours phosphonate thymidine uptake (% of control)
concentration (μM) WEHI-3B HL-60
Mean ± s.d., n=8
0 100 100
0.62 85 ± 3 93 ± 4
1.25 86 ± 4 81 ± 4
2.5 82 ± 6 66 ± 3
5 60 ± 4 16 ± 4
10 26 ± 3 5 ± 1
20 10 ± 3 1 ± 0.9
40 7 ± 3 3 ± 1
Effect of phosphonate of the following structure on thymidine
incorporation into DNA of WEHI-3B cells.
Table IV
Thymidine uptake after various days (% of control) phosphonate day 1 day 2 day 3 concentration (μM) Mean, n =5
0 100 100 100
1.25 95 84 77
2.5 72 67 54
5 34 22 12
10 18 13 10
20 8 2 1
40 3 2 2
Table V demonstrates the effect of phosphonate of the above structure on the incorporation of thymidine into DNA of the C-41 cell line (a human cervical tumor cell) Table V
Thymidine uptake into DNA of C-41 cell line phosphonate thymidine uptake (% of control) concentration (μM) Mean, n=3
0 100
2.5 88
5 63
10 42
20 41
40 16
Table VI shows the effect of the above phosphonate on tumor growth in mice. BALB/C mice were injected with 3-Lewis lung carcinoma under the skin at the back. Three days after injection of tumor cells the treatment was initiated with 50 mg/day orally once a day. In the control group the mice received only the carrier mucilage of tragacanth. As seen in Table VI, in control animals the first sign of a detectable tumor was observed after the seventh day of post cell injection. In the phosphonate-treated animals, the tumor growth was retarded by approximately 6 days. The tumor size in the
phosphonate-treated animals remained below that in the control animals throughout the experiments. Table VI
Days after tumor implant Tumor volume (mm3)
control + phosphonate
0 0 0
7 30 0
10 120 0
17 250 100
18 432 175
20 670 252
22 810 500
2. Anti-inflammatory activity
Example 1: Effect of the phosphonate of the following formula on the activation of human neutrophils
Superoxide anion generation in neutrophils has been used as an index of cell activation. The continuous spectrophotometric measurement of a superoxide dismutase inhibitable reduction of ferricytochrome C at 549 nm was used to demonstrate superoxide anion generation.
Human neutrophils were stimulated with 1 μM FMLP (N-formylmethionyl-leucyl-phenylalanine). A rapid generation of
superoxide was observed. Table VII shows the inhibition of
superoxide anion generation by 10 μM phosphonate after various
times.
Table VII
Time (min) absorbance at 549 nm
control FMLP FMLP + phosphonate
0 0 0 0
1 0.001 0.1 0.03
2 0.002 0.14 0.04
3 0.01 0.16 0.04
4 0.015 0.16 0.04
Example 2: Effect of phosphonate on neutrophil degranulation and lysosomal enzyme release (elastase)
Petri dishes were coated with [3H]elastin and were used to assess the release of elastase. Neutrophils (106) in 500 μl of medium were added to each Petri dish well. Addition of 1 μM FMLP for 1 hour at 37°C
stimulated elastase release as determined by the breakdown of
elastin. Phosphonate inhibited the neutrophil degranulation and the
release of elastase (Table VIII). Table VIIl phosphonate μg elastin degraded/106 cells/hr concentration (μM) Mean, n = 3
0 17
2.5 16
5 8
10 6
25 4
50 3
3. Anti-arthritis activity of phosphonates
In the synovial fluids of patients with arthritis there is an
accumulation of two types of crystals, calcium pyrophosphate dihydrate (CPPD) and monosodium urate (MSU). These two crystals types are the major contributors to the development of arthritis by causing rapid leukocyte activation. Table IX shows that phosphonates (50 μM) inhibited leukocyte activation in response to CPPD. Table X shows the inhibition in response to MSU.
Table IX
Time (min) chemiluminescence (mV)
CPPD CPPD + phosphonate
0 0 0
1 25 0
2 175 0
3 500 100
4 750 275
5 900 300
6 800 250
7 500 150
Table X
Time (min) chemiluminescence (mV)
MSU MSU+ phosphonate
0 0 0
1 200 10
2 500 50
3 600 75 4 675 80 5 550 50 6 400 20 4. Anti-allergic activity of phosphonates
Asthma is an allergic disease caused by the contraction of airway
smooth muscles in response to activation with contractile agonists such as leukotriene D4 (LTD4). As seen in Table XI, phosphonates at 5 μM inhibited LTD4-induced contraction of trachea from guinea pigs.
Table XI
LTD4 dose (μM) contraction (% of max carbachol) no phosphonate with phosphonate
0 0 0
0.01 7 0
0.1 21 0
1 45 0
10 50 8
Inhibition of tracheal smooth muscle contraction by phosphonates
supports the anti-allergic and asthmatic properties of these agents.
5. Anti-thrombolytic and cardiovascular activity
Thrombosis is the result of activation of platelets by agents such as
platelet activating factor (PAF). Platelet activation is associated with aggregation and release of vasoactive compounds such as serotonin
that have profound effects on heart and vascular tissues. The effects of phosphonate on aggregation of platelets caused by PAF or thrombin are shown in Table XII. As seen in Table XII, PAF at 1 μM or thrombin at 1 unit/ml caused 60-70% aggregation of platelets. In the presence of various concentrations of phosphonate a
dose-dependent inhibition of platelet aggregation is obtained. At 10 μM of phosphonate, a complete inhibition of platelet aggregation is seen.
Table XII phosphonate dose (μM) platelet aggregation (% of control)
thrombin (1 unit) PAF (1 μM)
0 100 100 0.5 58 74
1 29 48
5 7.5 26
10 0 0
Phosphonates also inhibited serotonin release from platelets activated with thrombin or PAF. As seen in Table XIII, phosphonate at 10 μM blocked serotonin release entirely.
Table XIII
phosphonate dose (mM) serotonin release (% of control)
thrombin (1 unit) PAF (1 μM)
0 100 100 1 76 80
5 36 48
10 16 28
The data in Table XIII support the anti-cardiovascular disease activity of phosphonates.
6. Anti-hypotensive activity
Administration of PAF intravenously causes severe hypotension.
Phosphonates were shown' to block PAF-induced hypotension in rats. When given at 5 mg/kg, phosphonates inhibited the hypotensive activity of PAF dramatically. As seen in Table XTV, normal rat blood pressure was about 150 mm Hg, and this dropped to about 40 mm Hg after administration of PAF (10 μg/kg). Animals given phosphonates (5 mg/kg) had only slightly reduced blood pressure after the injection of PAF, suggesting that phosphonates are anti-hypotensive agents.
Table XIV
PAF dose (μg/kg) blood pressure (mm Hg)
no phosphonate with phosphonate
0 150 148
0.5 135 145
1 120 145
2.5 100 140
5 60 140
10 40 130
These data strongly support the anti-hypotensive and cardiovascular activity of phosphonates.
Usage and Dosage
An effective concentration of phosphonate (normally 5-50 mg/l) can be given orally, intravenously (i.v.), intramuscularly (i.m.) or subcutaneously (s.c.), in the form of tablets (orally), capsules (orally), or injection ampules (i.v., i.m., s.c). The drug can be applied in the form of a rubbing cream. Tablets can be prepared via compression of 50 mg of phosphonates, 200 mg of lactose, and 50 mg Avicel(TM). Capsules are made by making bilayers of liposomal phosphonates in the concentrations of 5-50 mg with lecithin. Injection solutions are made either in water or propylene glycol with an upwardly adjusted pH in phosphate buffer. The drag solution is sterilized through a filter of 0.22 mm. Solutions can be made in 20% propylene glycol with about 0.5% of a preservative such as ascorbic acid.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this invention without departing from the spirit or scope thereof.

Claims

What is claimed is:
1. A compound of the formula:
wherein n is 0 to 14 and R1 is an alkyl group of C12-C20 ; wherein R2 is a methyl group; and wherein R3 is an inositol analog head group, a (C H2)mN+(CH3)3 group with m = 2 to 10, a serine head group, or an ethanolamine head group.
2. A phosphonate compound of the formula:
wherein R is an alkyl group such as hexadecyl or octadecyl, m = 0 or 1, n = 2 - 10, or the enantiomer thereof, or a mixture of stereoisomers.
3. Phosphonolipids of the general formula R-P(O)(O-)OR' wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
4. Phosphinates of the general formula:
wherein n = 0 or 1, R1 and R2 are as defined in claim 1, and R3 is an inositol or N+(R4)3 group and m = 2 - 10, and R4 is an alkyl group such as methyl, ethyl, n-propyl, or isopropyl.
5. A phosphonate compound as claimed in claims 1 and 2 including either of the opposite stereochemical configurations [(R) or (S)], or the mixture thereof.
6. A phosphinate for treatment of leukemic cells having the formula:
wherein R1 is a long-chain alkyl group, R2 is a methyl group, n = 0 or 1, m = 2 or 3, and R3 is N+(CH3)3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
7. A compound as claimed in claim 1 used as an agent in inhibiting cancer cell growth when the compound is administered at a concentration in the range of 5 mg/l to 50 mg/l, and pharmaceutically acceptable acid or salts thereof; and a pharmaceutically acceptable carrier.
8. A compound as claimed in claim 1 used in the treatment of an inflammatory disease administered at 5-50 mg/l in a
pharmaceutically acceptable carrier.
9. A compound as claimed in claim 2 used in the treatment of an inflammatory disease administered at 5-50 mg/l in a
pharmaceutically acceptable carrier.
10. A compound as claimed in claim 3 used in the treatment of an inflammatory disease administered at 5-50 mg/l in a
pharmaceutically acceptable carrier.
11. A compound as claimed in claim 4 used in the treatment of an inflammatory disease administered at 5-50 mg/l in a
pharmaceutically acceptable carrier.
12. A phosphonate or phosphinate as defined in claim 1 or 4 used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
13. A phosphonate or phosphinate as defined in claim 2 or 4 used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
14. A phosphonate or phosphinate as defined in claim 3 or 4 used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
15. A phosphonate or phosphinate as defined in claim 1 or 4 used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular diseasewhen admimstered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
16. A phosphonate as defined in claim 5 used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
17. A method of treating; cancer, inflammation, allergy or
cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a compound of the formula:
wherein n is 0 to 14 and R1 is an alkyl group of C12-C20 ; wherein R2 is a methyl group; and wherein R3 is an inositol analog head group, a (CH2)mN+(CH3)3 group with m = 2 to 10, a serine head group, or an ethanolamine head group.
18. A method of treating cancer, inflammation, allergy or
cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a compound of the formula:
wherein R is an alkyl group such as hexadecyl or octadecyl, m = 0 or 1, n = 2 - 10, or the enantiomer thereof, or a mixture of stereoisomers.
19. A method of treating cancer, inflammation, allergy or
cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphonolipid of the general formula: R-P(O)(O-)(OR), wherein R is an alkyl group such as hexadecyl or octadecyl and R' is a head group such as choline, glycerol, inositol, ethanolamine, or serine.
20. A method of treating cancer, inflammation, allergy or
cardiovascular disease in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate of the general formula:
wherein n = 0 or 1, R1 and R2 are as defined in claim 1, and R3 is an inositol or N+(R4)3 group and m = 2 - 10, and R4 is an alkyl group such as methyl, ethyl, n-propyl, or isopropyl.
21. A method as claimed in claim 17 or 18 wherein the phosphonate or phosphinate compound includes either of the opposite
stereochemical configurations [(R) or (S)], or the mixture thereof.
22. A method of treating leukemic cells in a mammal comprising treating the mammal with a therapeutic amount of a phosphinate having the formula:
wherein R1 is a long-chain alkyl group, R2 is a methyl group, n = 0 or
1, m = 2 or 3, and R3 is N+(CH3)3 , and pharmaceutically acceptable salts thereof, administered at a dosage of about 5 to 50 mg/l, with or without a carrier.
23. A method as claimed in claim 17 wherein the compound is used as an agent in inhibiting cancer cell growth when the compound is administered at a concentration in the range of 5 mg/l to 50 mg/l, and pharmaceutically acceptable acid or salts thereof; and a
pharmaceutically acceptable carrier.
24. A method as claimed in claim 17 wherein the compound is used in the treatment of an inflammatory disease administered at 5-50 mg/l in a pharmaceutically acceptable carrier.
25. A method as claimed in claim 17 wherein the phosphonate or phosphinate is used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a
pharmaceutically acceptable carrier.
26. A method as claimed in claim 20 wherein the phosphonate or phosphinate is used in the treatment of allergic skin rashes, hayfever, and asthma or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
27. A phosphonate or phosphinate as defined in claim 3 used in the treatment of allergic skin rashes, hayfever, and asthma or
cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
28. A phosphonate or phosphinate as defined in claim 4 used in the treatment of allergic skin rashes, hayfever, and asthma or
cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
29. A phosphonate or phosphinate as defined in claim 5 used in the treatment of allergic skin rashes, hayfever, and asthma, or cardiovascular disease when administered to the patient at a dosage of about 5-50 mg/l in association with a pharmaceutically acceptable carrier.
EP19920908170 1991-04-25 1992-04-21 Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents Withdrawn EP0581793A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69245291A 1991-04-25 1991-04-25
US692452 1991-04-25

Publications (1)

Publication Number Publication Date
EP0581793A1 true EP0581793A1 (en) 1994-02-09

Family

ID=24780645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920908170 Withdrawn EP0581793A1 (en) 1991-04-25 1992-04-21 Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents

Country Status (2)

Country Link
EP (1) EP0581793A1 (en)
WO (1) WO1992019627A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600194D0 (en) * 1996-01-19 1996-01-19 Perstorp Ab A new chemical compound
WO2002067855A2 (en) * 2001-02-21 2002-09-06 The Research Foundation Of The City University Of New York Enantiomers of unsaturated alkyllysophosphonocholines and use as anti-neoplastics
WO2004062594A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds with modifications at the sn-3 carbon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (en) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Use of a lysolecithin for tumor treatment
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
JPS5984824A (en) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd Antitumor agent
US4640913A (en) * 1983-01-10 1987-02-03 American Cyanamid Company Phosphocholine derivatives having antihypertensive action
ES2056998T3 (en) * 1988-04-19 1994-10-16 Asta Medica Ag PROCEDURE FOR OBTAINING NEW ALKYLPHOSPHONOSERINS.
JPH0669088A (en) * 1992-03-26 1994-03-11 Nec Kyushu Ltd Air-conditioning system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9219627A2 *

Also Published As

Publication number Publication date
WO1992019627A2 (en) 1992-11-12
WO1992019627A3 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
US5369097A (en) Phosphonates as anti-cancer agents
US5260288A (en) Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
AU651835B2 (en) Phosphorous prodrugs
CA1338627C (en) Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
Starrett et al. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy) ethyl] adenine (PMEA)
KR100874392B1 (en) LPA agonists and antagonists, and methods of use
EP0050460B1 (en) Tridecyloxy- or tetradecyloxy-propane derivatives, and their use
CA1227792A (en) Phosphinylalkanoyl substituted imino acids
US4804789A (en) D-mannite derivatives as starting products for the synthesis of phospholipids
JP3218313B2 (en) Elsyl-, brassyl- and nerbonyl derivatives, methods for their preparation, medicaments for combating diseases caused by tumors and protozoa and fungi containing them, medicaments for the treatment of autoimmune diseases and bone marrow disorders, and methods for producing the medicaments
US20130190524A1 (en) Cyclitols and their derivatives and their therapeutic applications
EP0040039B1 (en) Ethylene glycol derivatives of ammonioethyl phosphate, their production and use
US5219845A (en) Phosphonates as anti-inflammation agents
EP0099068B1 (en) Glycerine derivatives for phospholipids synthesis
Rosenthal [48] Chemical synthesis of phospholipids and analogues of phospholipids containing carbon-phosphorus bonds
EP0581793A1 (en) Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents
WO1998009668A2 (en) Use of amphiphiles as phosphatidyl choline synthesis inhibitors
KR20040035807A (en) Lpa receptor agonists and antagonists and methods of use
US6172050B1 (en) Phospholipid derivatives
CA2100228C (en) Phospholipid derivatives
US5506217A (en) Phosphonates as anti-cancer agents
US4647685A (en) 2-alkoxy-1-((2-trialkylaminoethoxy)phosphinyloxy)-alkenes and alkynes, hydroxy inner salts
US5916884A (en) Compositions containing a mixture of phosphorus compounds and alkylglycerols
EP1019418B1 (en) Inositol derivatives and pharmaceutical compositions comprising them
US20020173489A1 (en) Compositions containing a mixture of phosphorous compounds and alkylglycerols

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB GR IT LI LU MC PT

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK FR GB GR IT LI LU MC

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC

17Q First examination report despatched

Effective date: 19970115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970726